A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02257372 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: UMEC DPI
DRUG: Placebo DPI
DRUG: ICS/LABA medication
DRUG: Albuterol/salbutamol Metered Dose Inhaler (MDI)

Sponsor

GlaxoSmithKline